Rockland Trust Co. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 158,243 shares of the company’s stock after selling 668 shares during the period. Johnson & Johnson accounts for about 3.1% of Rockland Trust Co.’s investment portfolio, making the stock its 2nd largest position. Rockland Trust Co.’s holdings in Johnson & Johnson were worth $19,709,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in the stock. Lenox Wealth Advisors Inc. raised its position in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares during the last quarter. Landmark Financial Advisors LLC raised its position in Johnson & Johnson by 0.5% in the fourth quarter. Landmark Financial Advisors LLC now owns 1,948 shares of the company’s stock valued at $224,000 after buying an additional 10 shares during the last quarter. Berson & Corrado Investment Advisors LLC raised its position in Johnson & Johnson by 0.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 2,835 shares of the company’s stock valued at $353,000 after buying an additional 19 shares during the last quarter. Liberty Capital Management Inc. raised its position in Johnson & Johnson by 0.7% in the first quarter. Liberty Capital Management Inc. now owns 7,226 shares of the company’s stock valued at $900,000 after buying an additional 50 shares during the last quarter. Finally, Dynamic Advisors Solutions LLC raised its position in Johnson & Johnson by 0.3% in the first quarter. Dynamic Advisors Solutions LLC now owns 19,487 shares of the company’s stock valued at $2,427,000 after buying an additional 56 shares during the last quarter. Hedge funds and other institutional investors own 66.02% of the company’s stock.
Shares of Johnson & Johnson (NYSE JNJ) opened at 132.15 on Tuesday. The company has a market cap of $355.99 billion, a P/E ratio of 22.21 and a beta of 0.78. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.00. The firm has a 50-day moving average of $130.42 and a 200-day moving average of $122.68.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.77 by $0.06. The business had revenue of $17.77 billion during the quarter, compared to analysts’ expectations of $18.02 billion. Johnson & Johnson had a net margin of 22.87% and a return on equity of 26.50%. The business’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the company posted $1.68 earnings per share. Equities research analysts forecast that Johnson & Johnson will post $7.10 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.54%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.47%.
COPYRIGHT VIOLATION WARNING: This story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://sportsperspectives.com/2017/07/18/johnson-johnson-jnj-position-lowered-by-rockland-trust-co.html.
Several equities analysts have recently issued reports on the stock. UBS AG reiterated a “buy” rating and set a $136.00 target price on shares of Johnson & Johnson in a report on Monday, May 15th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 target price for the company in a report on Thursday, May 18th. Stifel Nicolaus reiterated a “hold” rating and set a $128.00 target price (up from $124.00) on shares of Johnson & Johnson in a report on Thursday, May 18th. BidaskClub upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Finally, Wells Fargo & Company restated a “market perform” rating and issued a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Eleven analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Hold” and an average price target of $133.65.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.